What type of study is this?

This is a Human Clinical Trial study (also classified as: Pre-Registered Trial).

December 8, 2025Blood

Using a medically trained LLM-based end-to-end system in automating patient eligibility screening across a health system for A phase 3 study evaluating the safety of givinostat in patients with polycythemia vera.

View Full Paper

Ask AI

Bookmark

Synapsis AI identified 22 eligible patients for the GIV-IN PV trial, demonstrating remarkable efficacy in screening.
The LLM-based system achieved 100% accuracy in patient eligibility assessments compared to manual methods.
Traditional screening identified only 4 patients over a year, contrasting with Synapsis AI's rapid, large-scale assessment.
Enhanced recruitment processes using AI may support faster clinical trials and development of therapies for rare diseases.

No takes yet. Share an insight, caveat, or question.

Trial recruitment shows improved screening efficiency in polycythemia vera patients, indicating LLM technology's promise for rare diseases.

Vecchio et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Trial recruitment shows improved screening efficiency in polycythemia vera patients, indicating LLM technology's promise for rare diseases.